Champions Oncology, Inc. (CSBR) — Financial statements
Income statement, balance sheet, and cash flow for Champions Oncology, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 57↑13.5% | 50↓6.9% | 54↑9.7% | 49↑19.7% | 41 | |
| Cost of Revenue | 30↑2.1% | 29↓0.4% | 30↑25.0% | 24↑10.2% | 21 | |
| Gross Profit | 27↑29.7% | 21↓14.7% | 24↓4.5% | 25↑30.0% | 20 | |
| Operating Expenses | ||||||
| R&D Expenses | 7↓28.5% | 10↓17.3% | 12↑23.2% | 9↑30.3% | 7 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 15↓15.9% | 18↑5.2% | 17↑11.3% | 15↑28.8% | 12 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 22↓20.3% | 28↓3.9% | 29↑15.7% | 25↑29.3% | 19 | |
| Total Costs & Expenses | 52↓8.7% | 57↓2.1% | 58↑20.2% | 49↑19.2% | 41 | |
| Operating Results | ||||||
| Operating Income | 5↑170.0% | -7↓55.6% | -4↓832.9% | 0.61↑65.8% | 0.37 | |
| Depreciation & Amortization | 2↓12.2% | 2↓41.6% | 3↑32.5% | 2↑52.5% | 2 | |
| EBITDA | 6↑216.3% | -5↓161.6% | -2↓169.1% | 3↑48.4% | 2 | |
| EBIT | 5↑163.9% | -7↓38.2% | -5↓1003.4% | 0.58↑33.4% | 0.44 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.06↓6.3% | 0.06 | 0.00↑100.0% | -0.02 | 0.00 | |
| Interest Income | 0.09↓5.4% | 0.09 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.03↓3.6% | 0.03 | 0.00↓100.0% | 0.02 | 0.00 | |
| Non-Operating Income | 0.19↓46.2% | 0.36↓56.1% | 0.82↑3308.3% | 0.02↑133.8% | -0.07 | |
| Other Income / Expenses | -0.22↑43.2% | -0.39↑52.7% | -0.82↓3308.3% | -0.02↓133.8% | 0.07 | |
| Income Before Tax | 5↑163.3% | -7↓38.8% | -5↓1003.4% | 0.58↑33.4% | 0.44 | |
| Income Tax Expense | -0.08↓134.4% | -0.03↓147.1% | 0.07↑94.3% | 0.04↓53.3% | 0.08 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 5↑164.6% | -7↓36.4% | -5↓1073.5% | 0.55↑51.4% | 0.36 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 5↑164.6% | -7↓36.4% | -5↓1073.5% | 0.55↑51.4% | 0.36 | |
| Bottom-Line Net Income | 5↑164.6% | -7↓36.4% | -5↓1073.5% | 0.55↑51.4% | 0.36 | |
| EPS (Basic) | 0.34↑163.0% | -0.54↓38.5% | -0.39↓1039.8% | 0.04↑50.4% | 0.03 | |
| EPS (Diluted) | 0.33↑161.1% | -0.54↓38.5% | -0.39↓1107.8% | 0.04↑56.0% | 0.02 | |
| Weighted Average Shares | 14↑0.8% | 14↑0.0% | 14↑2.6% | 13↑0.4% | 13 | |
| Weighted Average Diluted Shares | 14↑5.3% | 14↑0.0% | 14↓4.4% | 14↓2.8% | 15 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.